Obstructive coronary artery disease (CAD) limits maximal myocardial perfusion and demand ischemia reduces regional myocardial contraction. Glucagon-like peptide-1 (GLP-1) may potentially protect the myocardium from ischemic dysfunction by reducing fatty acid oxidation. Sitagliptin is a DDP-4 inhibitor licensed for the treatment of Type 2 Diabetes Mellitus (T2DM) that reduces degradation of plasma GLP-1 (7-36). We investigated whether sitagliptin improved myocardial performance during dobutamine stress echocardiography (DSE) in patients with T2DM and CAD.
